Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study

OBJECTIVE: In the Phase III PAOLA study (clinicaltrials.gov: NCT01137682), enrolled patients had uncontrolled acromegaly despite ≥6 months of octreotide/lanreotide treatment before study start. More patients achieved biochemical control with long-acting pasireotide versus continued treatment with oc...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Endocrinol
Main Authors: Colao, Annamaria, Bronstein, Marcello D, Brue, Thierry, De Marinis, Laura, Fleseriu, Maria, Guitelman, Mirtha, Raverot, Gerald, Shimon, Ilan, Fleck, Jürgen, Gupta, Pritam, Pedroncelli, Alberto M, Gadelha, Mônica R
Format: Artigo
Language:Inglês
Published: Bioscientifica Ltd 2020
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7222286/
https://ncbi.nlm.nih.gov/pubmed/32217809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-19-0762
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items